Effectiveness of Long-Term Physiotherapy in Parkinson's Disease: A Systematic Review and Meta-Analysis.
Parkinson’s disease
Physiotherapy
meta-analysis
motor symptoms
randomized controlled trial
systematic review
Journal
Journal of Parkinson's disease
ISSN: 1877-718X
Titre abrégé: J Parkinsons Dis
Pays: Netherlands
ID NLM: 101567362
Informations de publication
Date de publication:
2021
2021
Historique:
pubmed:
10
8
2021
medline:
15
12
2021
entrez:
9
8
2021
Statut:
ppublish
Résumé
Long-term physiotherapy is acknowledged to be crucial to manage motor symptoms for Parkinson's disease (PD) patients, but its effectiveness is not well understood. This systematic review and meta-analysis aimed to assess the evidence regarding the effectiveness of long-term physiotherapy to improve motor symptoms and reduce antiparkinsonian medication dose in PD patients. Pubmed, Cochrane, PEDro, and CINAHL were searched for randomized controlled trials before August 31, 2020 that investigated the effectiveness of physiotherapy for 6 months or longer on motor symptoms and levodopa-equivalent dose (LED) in PD patients with Hoehn and Yahr stage 1- 3. We performed random effects meta-analyses for long-term physiotherapy versus no/control intervention and estimated standard mean differences with 95% confidence intervals (CIs). Levels of evidence were rated by the Grading of Recommendation Assessment, Development and Evaluation approach. From 2,940 studies, 10 studies involving 663 PD patients were assessed. Long-term physiotherapy had favorable effects on motor symptoms in off medication state [- 0.65, 95% CI - 1.04 to - 0.26, p = 0.001] and LED [- 0.49, 95% CI - 0.89to - 0.09, p = 0.02]. Subgroup analyses demonstrated favorable effects on motor symptoms in off medication state by aerobic exercise [- 0.42, 95% CI - 0.64 to - 0.20, p < 0.001] and LED by multidisciplinary rehabilitation of primarily physiotherapy [- 1.00, 95% CI - 1.44 to - 0.56, p < 0.001]. Quality of evidence for aerobic exercise and multidisciplinary rehabilitation were low and very low. This review provided evidence that long-term physiotherapy has beneficial impact on motor symptoms and antiparkinsonian medication dose in PD patients and could motivate implementation of long-term physiotherapy.
Sections du résumé
BACKGROUND
Long-term physiotherapy is acknowledged to be crucial to manage motor symptoms for Parkinson's disease (PD) patients, but its effectiveness is not well understood.
OBJECTIVE
This systematic review and meta-analysis aimed to assess the evidence regarding the effectiveness of long-term physiotherapy to improve motor symptoms and reduce antiparkinsonian medication dose in PD patients.
METHODS
Pubmed, Cochrane, PEDro, and CINAHL were searched for randomized controlled trials before August 31, 2020 that investigated the effectiveness of physiotherapy for 6 months or longer on motor symptoms and levodopa-equivalent dose (LED) in PD patients with Hoehn and Yahr stage 1- 3. We performed random effects meta-analyses for long-term physiotherapy versus no/control intervention and estimated standard mean differences with 95% confidence intervals (CIs). Levels of evidence were rated by the Grading of Recommendation Assessment, Development and Evaluation approach.
RESULTS
From 2,940 studies, 10 studies involving 663 PD patients were assessed. Long-term physiotherapy had favorable effects on motor symptoms in off medication state [- 0.65, 95% CI - 1.04 to - 0.26, p = 0.001] and LED [- 0.49, 95% CI - 0.89to - 0.09, p = 0.02]. Subgroup analyses demonstrated favorable effects on motor symptoms in off medication state by aerobic exercise [- 0.42, 95% CI - 0.64 to - 0.20, p < 0.001] and LED by multidisciplinary rehabilitation of primarily physiotherapy [- 1.00, 95% CI - 1.44 to - 0.56, p < 0.001]. Quality of evidence for aerobic exercise and multidisciplinary rehabilitation were low and very low.
CONCLUSION
This review provided evidence that long-term physiotherapy has beneficial impact on motor symptoms and antiparkinsonian medication dose in PD patients and could motivate implementation of long-term physiotherapy.
Identifiants
pubmed: 34366377
pii: JPD212782
doi: 10.3233/JPD-212782
pmc: PMC8609713
doi:
Substances chimiques
Antiparkinson Agents
0
Levodopa
46627O600J
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1619-1630Références
Mov Disord. 2010 Nov 15;25(15):2649-53
pubmed: 21069833
BMJ. 2009 Jul 21;339:b2700
pubmed: 19622552
Neurorehabil Neural Repair. 2020 Oct;34(10):871-880
pubmed: 32917125
Neurology. 2010 Apr 6;74(14):1143-8
pubmed: 20368634
BMJ. 2008 Apr 26;336(7650):924-6
pubmed: 18436948
J Neural Transm (Vienna). 2018 Jan;125(1):35-43
pubmed: 28091751
JAMA Neurol. 2018 Jan 1;75(1):9-10
pubmed: 29131880
Mov Disord. 2008 Nov 15;23(15):2129-70
pubmed: 19025984
Acta Neurol Scand. 2011 Jan;123(1):20-7
pubmed: 20199514
Neurotherapeutics. 2020 Oct;17(4):1418-1433
pubmed: 32808252
Phys Ther. 2012 Nov;92(11):1395-410
pubmed: 22822237
Lancet Neurol. 2019 Nov;18(11):998-1008
pubmed: 31521532
Med Sci Sports Exerc. 2014 Apr;46(4):645-55
pubmed: 24002341
Med Sci Sports Exerc. 2019 Feb;51(2):237-245
pubmed: 30303934
Neurorehabil Neural Repair. 2012 Feb;26(2):144-50
pubmed: 21844282
Mov Disord. 2009 Jan 15;24(1):1-14
pubmed: 18946880
Mov Disord. 2008 Apr 30;23(6):790-6
pubmed: 18361474
Mov Disord. 2020 Oct;35(10):1719-1720
pubmed: 32926470
Mov Disord. 2003 Jul;18(7):738-50
pubmed: 12815652
Lancet Neurol. 2014 Jun;13(6):557-66
pubmed: 24726066
JAMA Neurol. 2018 Feb 1;75(2):219-226
pubmed: 29228079
Arq Neuropsiquiatr. 2018 Aug;76(8):499-506
pubmed: 30231121
Brain. 2000 Nov;123 ( Pt 11):2297-305
pubmed: 11050029
Mov Disord. 2013 Aug;28(9):1230-40
pubmed: 23536417
JAMA. 2020 Feb 11;323(6):548-560
pubmed: 32044947
Lancet Neurol. 2013 Jul;12(7):716-26
pubmed: 23769598
Eur J Neurol. 2015 Mar;22(3):457-63
pubmed: 24888502
Cochrane Database Syst Rev. 2012 Jul 11;(7):CD002817
pubmed: 22786482
Nat Rev Neurol. 2017 Nov;13(11):689-703
pubmed: 29027544
Neurorehabil Neural Repair. 2015 Feb;29(2):123-31
pubmed: 25038064
J Neurol Neurosurg Psychiatry. 2018 Sep;89(9):1003-1005
pubmed: 28607121